Dana-Farber - Harvard Cancer Center LAO

Boston, Massachusetts 02115

0 studies enrolling now · 1 studies all time

What they study most

Refractory Myelodysplastic Syndrome

Studies at this site

• Testing an Anti-cancer Radio-Active Immunotherapy Called Lintuzumab Ac225 in Patients With High-Risk Myelodysplastic Syndrome That Has Not Responded to Other Treatment — Paused